Synthesis and Biological Activity of Bile Acid-Derived HMG-CoA Reductase Inhibitors. The Role of 21-Methyl in Recognition of HMG-CoA Reductase and the Ileal Bile Acid Transport System

Journal of Medicinal Chemistry
1994.0

Abstract

To increase hepatoselectivity of HMG-CoA reductase inhibitors by using the specific bile acid transport systems, deoxycholic acid-derived inhibitors 9 and 11 have been synthesized, on the basis of the concept of combining in one molecule structural requirements for specific inhibition of the HMG-CoA reductase and specific recognition by the ileal bile acid transport system. The 1-methyl-3-carboxylpropyl subunit of deoxycholic acid was replaced by the 3,5-dihydroxyheptanoic acid lactone of lovastatin, and position 12-OH was esterified with 2-methylbutyric acid. Compounds 9 and 11 were evaluated for their inhibitory activity on rat liver HMG-CoA reductase, cholesterol biosynthesis in HEP G2 cells, and [3H]taurocholate uptake in rabbit brush border membrane vesicles and compared with methyl derivatives 8 and 10. The steroidal 21-CH3 group affects both activity on HMG-CoA reductase and recognition by the ileal bile acid transport system.

Knowledge Graph

Similar Paper

Synthesis and Biological Activity of Bile Acid-Derived HMG-CoA Reductase Inhibitors. The Role of 21-Methyl in Recognition of HMG-CoA Reductase and the Ileal Bile Acid Transport System
Journal of Medicinal Chemistry 1994.0
Specific Inhibitors of Ileal Bile Acid Transport
Journal of Medicinal Chemistry 1994.0
Design and synthesis of hepatoselective, pyrrole-based HMG-CoA reductase inhibitors
Bioorganic & Medicinal Chemistry Letters 2007.0
Discovery of pyrrole-based hepatoselective ligands as potent inhibitors of HMG-CoA reductase
Bioorganic & Medicinal Chemistry 2007.0
Pyrazole inhibitors of HMG-CoA reductase: An attempt to dramatically reduce synthetic complexity through minimal analog re-design
Bioorganic & Medicinal Chemistry Letters 2007.0
Substituted Pyrazoles as Hepatoselective HMG-CoA Reductase Inhibitors: Discovery of (3R,5R)-7-[2-(4-Fluoro-phenyl)-4-isopropyl-5-(4-methyl-benzylcarbamoyl)-2H-pyrazol-3-yl]-3,5-dihydroxyheptanoic Acid (PF-3052334) as a Candidate for the Treatment of Hypercholesterolemia
Journal of Medicinal Chemistry 2008.0
Research and Development of Pravastatin
YAKUGAKU ZASSHI 1991.0
Hepatoselectivity of statins: Design and synthesis of 4-sulfamoyl pyrroles as HMG-CoA reductase inhibitors
Bioorganic & Medicinal Chemistry Letters 2008.0
Evaluation of biological activities, and exploration on mechanism of action of matrine–cholesterol derivatives
Bioorganic Chemistry 2020.0
Design and synthesis of bile acid derivatives and their activity against colon cancer
RSC Medicinal Chemistry 2022.0